ROCKVILLE, Md., March 7, 2017 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company
developing therapeutics that preserve the microbiome to protect and
restore the health of patients, announced today that Jeffrey Riley, President & Chief Executive
Officer, is scheduled to present at the 29th Annual ROTH
Conference being held March 12-15 at
the Ritz-Carlton, Laguna Niguel in
Dana Point, CA. Mr. Riley is
scheduled to present on Wednesday, March 15,
2016 at 8:00 a.m. (Pacific
Time)/11:00 a.m. (Eastern
Time).
A live webcast of Synthetic Biologics' presentation may be
accessed by logging onto the web at
http://wsw.com/webcast/roth31/syn. After the presentation, a replay
will be archived and accessible for 60 days at the same
website.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a late-stage
clinical company developing therapeutics designed to preserve the
microbiome to protect and restore the health of patients. The
Company's lead candidates poised for Phase 3 development are: (1)
SYN-010 which is intended to reduce the impact of methane producing
organisms in the gut microbiome to treat an underlying cause of
irritable bowel syndrome with constipation (IBS-C), and (2) SYN-004
(ribaxamase) which is designed to protect the gut microbiome from
the effects of certain commonly used intravenous (IV) beta-lactam
antibiotics for the prevention of C. difficile infection
(CDI), antibiotic-associated diarrhea (AAD) and the emergence of
antimicrobial resistance (AMR). The Company is also developing
preclinical stage monoclonal antibody therapies for the prevention
and treatment of pertussis and novel discovery stage
biotherapeutics for the treatment of phenylketonuria (PKU). For
more information, please visit Synthetic Biologics' website at
www.syntheticbiologics.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/synthetic-biologics-to-present-at-the-29th-annual-roth-conference-300418762.html
SOURCE Synthetic Biologics, Inc.